Arthritis Drugs for Critically Ill COVID-19 Patients

The immunosuppressive drugs Tocilizumab and Sarilumab improved survival and recovery time of intensive care of Covid-19 patients

The UK government encourages (https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103134) the use of c and Sarilumab, medications initially developed to improve arthritis symptoms, to treat severe COVID-19 cases.

The study, which has not yet been peer-reviewed, evaluating around 800 patients in intensive care with severe COVID-19, reports that half received the standard of care. In contrast, 353 received Tocilizumab, and 48 received Sarilumab. The researchers found that 35.8 percent of those given standard care died, compared with 28 percent who received Tocilizumab and 22.2 percent who were given Sarilumab.

We should ask: Why this data look different from other similar studies?

Two are the possible reasons:

1. Other published randomized trials primarily enrolled hospitalized patients with less severe disease.
2. Patients in this study also received the drugs within 24 hours of entering intensive care, suggesting that early treatment could be necessary for improving patient survival.

Dozens of clinical trials for the treatment of COVID-19 with Tocilizumab and Sarilumab are planned or underway.

Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.

"*" indicates required fields

NAME:*

EMAIL:*

PHONE NUMBER:

COMMENTS:*

CAPTCHA

Comments

This field is for validation purposes and should be left unchanged.